Ignite Creation Date:
2024-05-05 @ 11:32 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00079586
Status:
COMPLETED
Last Update Posted:
2012-01-05
First Post:
2004-03-09
Brief Title:
Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass CPB
Sponsor:
The Medicines Company
Organization:
The Medicines Company
Study Overview
Official Title:
A Study Comparing Angiomax Bivalirudin to Heparin With Protamine Reversal in Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass CPB
Status:
COMPLETED
Status Verified Date:
2012-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to demonstrate that in patients undergoing coronary artery bypass grafting CABG or CABG-Valve or Isolated Cardiac Valve surgery on CPB cardiac surgery Angiomax is a safe and effective alternative anticoagulant to heparin with protamine reversal
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EVOLUTION-On | None | None | None |